Investing.commacroeconomiaNEUTRALLOWBreaking

JPMorgan resumes BioCryst Pharma stock coverage with neutral rating

No summary available

Read at Investing.com

Also reported by

Also reported byInvesting.comInvesting.comInvesting.comInvesting.com